A part of Watch Media

Sunday2 April 2023

25/06/2021at 15:43

Top news from MedWatch this week

Miss anything?

Photo: MedWatch

BY MIKKEL AABENHUS HEMMINGSEN

Monday

Series of setbacks have not caused Orphazyme CEO to consider departing

FDA approves new Ambu product

Novo Nordisk CEO's pay sets itself apart on especially one point

Orphazyme not seeking fresh capital despite reduced cash position

Tuesday

Roche's digital health venture boosted by pandemic

Leo Pharma's new drug for atopic dermatitis receives EU approval

Financial analyst: Novo Nordisk's obesity treatment could triple market

Wednesday

US dermatology top boss moves to Danish biotech firm

Janssen gets expanded authorization for Genmab's Darzalex in EU

Leo Pharma receives UK approval for Adtralza

Thursday

Zealand Pharma sends blood sugar drug to US market

Oticon Medical gets FDA approval for cochlear implant

Novo Holdings sees golden opportunity in dialysis company, contributes to USD 245m investment

Friday

CHMP recommends eight new drugs for approval – one cancer drug rejected

Oticon president satisfied with FDA approval: "A huge milestone"

Pharmacosmos launches cell therapy market offensive

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Front page now

Per Wold-Olsen officially stepped down as GN's chair at the company's AGM | Foto: Mik Eskestad

Former GN chair says there have been no acquisition signs from Demant owner

Per Wold-Olsen left the chairperson position two weeks ago after 15 years – he now reveals there haven’t been acquisition talks behind closed doors during his time at the company.

For subscribers

Foto: Rob Acket/ema

CHMP recommends nine drugs in March

For subscribers

Nicolai Buhl, executive vice president for innovation at Coloplast, is busy winning a clinical contest against a catheter competitor | Foto: Mik Eskestad

Coloplast challenges its biggest catheter competitor in clinical contest

For subscribers

Foto: MedWatch

Top news from MedWatch this week

Foto: Bavarian Nordic / Pr

Pharma & biotech

Former Bavarian Nordic chairman sees opportunities in Johnson & Johnson's RSV exit

For subscribers

Foto: George Frey

Pharma & biotech

Novo Nordisk helps Canada resolve Ozempic issue

For subscribers

Further reading

Foto: George Frey

Pharma & biotech

Novo Nordisk helps Canada resolve Ozempic issue

Americans were reportedly crossing the border seeking the diabetes drug with a strong weight-loss effect until barred from purchases.

For subscribers

Minister for the Interior and Health of Denmark Sophie Løhde must answer questions concerning Novo Nordisk's funding of a Danish patient group | Foto: Ida Marie Odgaard

Pharma & biotech

Danish health minister to answer questions about Novo Nordisk sponsorship of patient group

The Danish minister for health has six business days to answer questions posed by a parliamentarian.

For subscribers

Per Wold-Olsen officially stepped down as GN's chair at the company's AGM | Foto: Mik Eskestad

Former GN chair says there have been no acquisition signs from Demant owner

Per Wold-Olsen left the chairperson position two weeks ago after 15 years – he now reveals there haven’t been acquisition talks behind closed doors during his time at the company.

For subscribers

Jobs